Researchers of a study aimed to evaluate the efficacy and safety of multiple doses of topical brepocitinib, a tyrosine kinase 2/JAK1 inhibitor, in patients with mild-to-moderate plaque psoriasis (PsO). The study was a phase 2b, multicenter, randomized, double-blind trial conducted in two stages. The study included 344 participants who were randomized to receive one of eight treatments for 12 weeks. Topical brepocitinib did not result in statistically significant changes from respective vehicle controls in the primary or key secondary efficacy endpoints for any dose group; however, brepocitinib was well-tolerated, and adverse events occurred at similar rates across groups. In conclusion, topical brepocitinib was well-tolerated but did not result in significant changes vs vehicle when given at the doses examined to treat signs and symptoms of mild-to-moderate PsO.
Reference: Landis MN, Smith SR, Berstein G, et al. Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb, randomised, double-blind, vehicle-controlled, parallel-group study [published online ahead of print, 2023 Mar 27]. Br J Dermatol. 2023;ljad098. doi:10.1093/bjd/ljad098
